Drugs / IVONESCIMAB
IVONESCIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07488572 | Nov 2025 → Jun 2027 expected | clear cell renal carcinoma | Sun Yat-sen University | Enrolling by invitation | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-22 | Arcus Biosciences, Inc. | Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer arcusbio.com ↗ |
| 2025-04-16 | CNBG-Virogin Biotech (Shanghai) Ltd. | Virogin Announces Collaboration of Second-Generation VG201 with Akeso’s AK112 for Colorectal Cancer Liver Metastasis virogin.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVONESCIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068451 ↗ |
| Known as | AK112 | “Yivoximab (AK112) is a human IgG1κ dual-target monoclonal antibody that simultaneously binds to PD-1 and VEGF.” NCT07488572 ↗ |
| Known as | SMT-112 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068451 ↗ |
| Known as | Yivoximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07488572 ↗ |
| Action | Inhibit | “enhance anti-tumor immune response by blocking immune checkpoint inhibition while inhibiting angiogenesis” NCT07488572 ↗ |
| Modality | Monoclonal antibody | “human IgG1κ dual-target monoclonal antibody” NCT07488572 ↗ |
| Route | Intravenous | “It is administered intravenously at a dose of 20 mg/kg every 3 weeks as monotherapy.” NCT07488572 ↗ |